Free Trial

Orion Oyj (ORINY) Stock Price, News & Analysis

0.00 (0.00%)
(As of 05/24/2024 ET)
Today's Range
50-Day Range
52-Week Range
135 shs
Average Volume
25 shs
Market Capitalization
$5.65 billion
P/E Ratio
Dividend Yield
Price Target
ORINY stock logo

About Orion Oyj Stock (OTCMKTS:ORINY)

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other international companies. Further, the company has partnership with Propeller Health to connect the Easyhaler(R) product portfolio; and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. to commercialize Amneal's generic products. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.

ORINY Stock Price History

ORINY Stock News Headlines

Orion Group Interim Report January–March 2024
Orion Group Interim Report January–March 2024
Orion Oyj goes ex dividend tomorrow
ORN Orion Group Holdings, Inc.
Orion Oyj just downgraded at Jefferies, here's why
Orion Oyj B (ORNBV)
87 000 Orion Corporation A shares converted into B shares
See More Headlines
Receive ORINY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Orion Oyj and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Fiscal Year End

Industry, Sector and Symbol

Private households
Current Symbol
Previous Symbol
Year Founded


Net Income
$234.62 million
Pretax Margin


Sales & Book Value

Annual Sales
$1.29 billion
Cash Flow
$1.48 per share
Book Value
$3.39 per share


Free Float
Market Cap
$5.65 billion
Not Optionable
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Liisa Hurme (Age 57)
    President, CEO & Chairman of Executive Management Board
    Comp: $823.82k
  • Mr. Jari Karlson M.Sc. (Age 63)
    M.Sc. (Econ.), CFO & Member of the Executive Management Board
  • Mr. Olli Huotari Ll.M. (Age 58)
    Senior VP of Corporate Functions, General Counsel, Secretary & Member of Executive Management Board
  • Ms. Satu Ahomäki M.Sc. (Age 58)
    M.Sc. (Econ.), Senior VP of Generics and Consumer Health Business Division & Member of the Exe. Mgmt. Board
  • Prof. Outi Vaarala M.D. (Age 62)
    Ph.D., Sr. VP of Innovative Medicines, Sr. VP of R&D and Member of the Exe. Mgmt. Board
  • Mr. Juhani Kankaanpaa
    Senior VP of Global Operations & Member of Executive Management Board
  • Mr. Niclas Lindstedt EMBA
    M.Sc., Senior VP of Animal Health Business Division & Member of the Exe. Mgmt. Board
  • Mr. Hao Pan M.Sc. (Age 53)
    Senior VP of the Branded Products Business Division & Member of the Exe. Mgmt. Board
  • Ms. Julia Irene Macharey (Age 47)
    Senior Vice President of People & Culture and Member of Management Board
  • Mr. Rene Lindell M.Sc. (Age 48)
    Ph.D., Member of Group Executive Management Board

ORINY Stock Analysis - Frequently Asked Questions

Should I buy or sell Orion Oyj stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Orion Oyj in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ORINY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ORINY, but not buy additional shares or sell existing shares.
View ORINY analyst ratings
or view top-rated stocks.

How have ORINY shares performed in 2024?

Orion Oyj's stock was trading at $20.70 at the start of the year. Since then, ORINY shares have decreased by 3.4% and is now trading at $20.00.
View the best growth stocks for 2024 here

How were Orion Oyj's earnings last quarter?

Orion Oyj (OTCMKTS:ORINY) released its quarterly earnings results on Thursday, April, 25th. The company reported $0.17 earnings per share (EPS) for the quarter. The business earned $334.95 million during the quarter. Orion Oyj had a net margin of 17.74% and a trailing twelve-month return on equity of 26.81%.

Is Orion Oyj a good dividend stock?

Orion Oyj (OTCMKTS:ORINY) pays an annual dividend of $0.36 per share and currently has a dividend yield of 1.85%. The dividend payout ratio is 42.86%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, ORINY will have a dividend payout ratio of 35.29% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for ORINY.

How do I buy shares of Orion Oyj?

Shares of ORINY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:ORINY) was last updated on 5/25/2024 by Staff

From Our Partners